NanoSteel Launches 3D Printable Tool Steel
NanoSteel®, the leader in nanostructured steel materials, today announced the launch of its first product for the laser powder bed fusion additive manufacturing process. BLDRmetal™ L-40 is a case-hardening steel powder that provides high hardness and ductility (case hardness >70HRC, 10%+ core elongation) and prints easily on standard commercial equipment. This alloy provides superior performance to M300 maraging steel and is an alternative to difficult-to-print tool steels such as H13. Expanding the potential use of 3D printing in a wide variety of hard materials markets, BLDRmetal™ L-40 is designed to be used for parts including tools, dies, bearings and gears.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170619005159/en/
Industrial die set printed using laser powder bed fusion with NanoSteel’s BLDRmetal™ L-40 tool steel (Photo: Business Wire)
The capabilities of BLDRmetal™ L-40 were demonstrated by printing an 8-inch roll thread die set, which outperformed dies machined from D2 and M2 tool steels. “We tried nearly every combination of material and conventional CNC machining process to create our dual-thread die sets, none of which could cut or grind the complicated dual-thread geometry,” said Mark Doll, President and CEO of Perfect Lock Bolt America Inc., the only manufacturer of dual-thread fasteners in North America that are resistant to self-loosening. “The NanoSteel solution delivers exactly what we are looking for, including excellent surface finish, flexibility, as well as strength and hardness for maximum die life. This is a welcomed technological innovation to the fastener industry. We have been pleased with our testing and are slated to start production this year.”
NanoSteel developed this high hardness alloy through rapid iterative development at CFK GmbH, an industry-leading 3D printing service provider, whose expertise was instrumental in developing the die from concept to finished part. “For us, the most important attributes of NanoSteel’s BLDRmetal™ L-40 are that it is easily implemented and creates crack-free high hardness components, which sets it apart from the many other tool steels we have tested” said Dr-Ing. Christoph Over, CEO at CFK. “We are proud to be a preferred printing service provider for NanoSteel, which will allow us to continue to offer the most valuable products to our customers.”
“Launching BLDRmetal™ L-40 after successfully producing the roll thread dies ensures the commercial viability of the new alloy for customers investigating the use of additive manufacturing,” said Harald Lemke, Vice President and General Manager of NanoSteel Engineered Powders. “We don’t stop at material design, but create joint solutions with our customers, facilitating the process from material selection and prototyping to fully qualified production parts.” Building off earlier products for binder jet printing, NanoSteel continues to expand its product family for additive manufacturing.
NanoSteel is an advanced materials company specializing in the design and commercialization of patented steels with exceptional mechanical properties. Current focus areas are sheet steel for automotive lightweighting applications and metal powders for 3D printing. Founded in 2002, NanoSteel is a privately held company funded by investors including GM Ventures, Lear Corporation and SPDG. For more information, visit www.nanosteelco.com or follow us on Twitter @NanoSteelCo.
Robyn Kennedy, 617-694-7373
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
P&G Advances Systemic Change for Gender Equality in Advertising at 2018 Cannes Lions Festival of Creativity18.6.2018 15:25 | Tiedote
The Procter & Gamble Company (NYSE: PG) today advanced its commitment to gender equality through a series of new actions, commitments and partnerships to increase diversity throughout the creative supply chain, leading to more accurate and positive portrayals of women in advertising and media, and driving growth and social good. Women and girls are inaccurately or negatively portrayed in 29 percent of ads and media programs*, and women continue to be underrepresented behind the camera: only 32 percent of Chief Marketing Officers, 33 percent of Chief Creative Officers and a mere 10 percent of Commercial Directors are women. These issues persist despite evidence that gender-equal ads perform 10 percent higher in trust and 26 percent higher in sales growth*. To address these issues, P&G has called for an aspiration to achieve 100% accurate and positive portrayals of women in advertising and media, supported by equal representation of women and men in the creative supply chain. P&G is lead
Norsk Titanium Marks Milestone in U.S. Production18.6.2018 15:00 | Tiedote
Norsk Titanium (NTi), the world’s first FAA-approved supplier of aerospace-grade, additive manufactured, structural titanium components, announced today a major milestone in qualified production. NTi’s Plattsburgh, New York Development and Qualification Center (PDQC) site was officially added to Boeing’s Qualified Producers List (QPL) on May 1 and initiated qualified production on May 15 by manufacturing its first part under the Boeing contract. This milestone is a culmination of recent company successes including certification under AS9100D and the October 2017 dedication of PDQC by New York Governor Andrew Cuomo. “We could not be prouder of our Plattsburgh, New York production operations as they put another stake in the ground for the continued success of Norsk Titanium and the state of New York,” said NTi’s Chief Operating Officer Tamara Morytko. “Receiving this qualification from Boeing, now qualifying two NTi sites for production across the globe, is a true vote of confidence in o
Avedro Announces Enrollment of First Patient in U.S. Pivotal Phase 3 Epi-on Corneal Cross-Linking Trial for Progressive Keratoconus18.6.2018 15:00 | Tiedote
Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that it has begun enrolling patients in a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of an epithelium-on (epi-on) corneal collagen cross-linking procedure to treat patients with progressive keratoconus. Keratoconus is a non-inflammatory eye condition in which the typically round dome-shaped cornea progressively thins and weakens and is the leading cause of penetrating keratoplasty (corneal transplant) in the United States1. The Phase 3 clinical trial, ACP-KXL-308, is a multicenter, randomized, controlled study of a novel corneal cross-linking procedure of 275 patients with progressive keratoconus across approximately 20 sites in the United States. As is typical for U.S. Food and Drug Administration (FDA) drug trials, investigational treatments are provided at no cost to participating patients. “As a practitioner who has treated many p
LG Chem Hosts Global Innovation Contest 2018 (GIC 2018)"Finding Innovations to Change the World"18.6.2018 14:00 | Tiedote
LG Chem (KRX: 051910) is exploring innovative technologies that will change the world. LG Chem announced that it would hold a Global Innovation Contest (GIC) for leading universities and research institutions around the world. This is the first time that a Korean chemical company is conducting technology contests for the entire world. From June 18th to September 30th, 2018, LG Chem will accept innovative technology ideas in five promising business areas: Energy, Environment, Functional materials, Bio technology and Platform technology. Global scholars and researchers who are interested in developing the next generation’s innovative technology and industry-academia collaboration research are welcomed to participate and submit the technical proposal through the official website (www.rnd.lgchem.com/global/gic). LG Chem will select internal experts and selection committees to evaluate the proposals considering technology innovation, marketability, and price competitiveness. Selected assign
Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)18.6.2018 14:00 | Tiedote
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, ages six and older, will be reimbursed in Sweden after concluding the three-party negotiations with TLV and the county councils. Reimbursement is effective from July 1. The innovative, long-term access agreement also provides a framework for the assessment and access of our future CF medicines. “We are delighted that people with CF in Sweden will join the thousands of others around the world who are already benefitting from our CF medicines,” said Simon Bedson, International General Manager at Vertex. “We commend the Swedish authorities for partnering with us on an innovative, long-term access agreement. In countries where Vertex remains actively involved in reimbursement discussions, we encourage these health authorities and governments to match the commitment
Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 10:06 | Tiedote
Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme